CRTI Translational Research Grants

The objective of the CRTI Translational Research Grants is to partner Masonic Cancer Center basic/translational and clinical scientists so as to foster the development of novel experimental therapeutic agents and to facilitate their testing in institutional Phase I/II and IND clinical trials. These grants will provide targeted investments to promising translational studies with the goal of opening a clinical trial within 36 months.

Apply now!

RFA PDF

Grant Program Contacts

Application process, requirements, eligibility:
Jessica Raines-Jones
Research Development Coordinator
612-624-8679
mccgrant@umn.edu

Applicability of research:
Deepa Kolaseri, PhD
dkolaser@umn.edu 

Grantees

2019
Clinical Translation of Oncolytic Adenovirus to facilitate Radioiodine Therapy and Imaging for Pancreatic Adenocarcinoma  
Julia Davydova, MD, PhD 
Department of Surgery, Medical School
 
Co-opting NKG2A inhibitory signaling for cancer immunotherapy  
Ingunn Stromnes, PhD, Department of Microbiology & Immunology, Medical School 
2018

Developing more effective regulatory T cell therapeutics using non-viral control of gene expression
Keli Hippen, PhD, Department of Pediatrics, Medical School
Bruce Blazar, MD, Department of Pediatrics, Medical School 

Endoglin, A Potential Novel Target for AML
Rita Perlingeiro, PhD, Department of Medicine, Medical School
Sarah Cooley, MD, Department of Medicine, Medical School

2017
Radioiodine-Based Therapy and Imaging for Pancreatic Cancer
Julia Davydova, MD, PhD, Department of Surgery, Medical School
Edward Greeno, MD, Department of Medicine, Medical School
 
Immune Response in Refractory Metastatic Melanoma Patients Undergoing Radiation Therapy
Evidio Domingo-Musibay, MD, Department of Medicine, Medical School
Heather Nelson, PhD, MPH, Department of Epidemiology and Community Health, School of Public Health 
2016

USP14 as an Independent Prognostic Biomarker and Therapeutic Target for Recurrent Endometrial Cancer
Martina Bazzaro, PhD, Department of Obstetrics, Gynecology and Women’s Health, Medical School
Melissa Geller, MD, Department of Obstetrics, Gynecology and Women’s Health, Medical School

IL-15 Superagonist ALT-803 for Treatment of Advanced Staged Ovarian Cancer
Melissa Geller, MD, Department of Obstetrics, Gynecology and Women’s Health, Medical School
Jeffrey Miller, MD, Department of Medicine, Medical School

eBAT (Epidermal Growth Factor Receptor (EGFR) Bispecific Angiotoxin) for the Treatment of EGFR Positive Malignancies
Brenda Weigel, MD, Department of Pediatrics, Medical School
Evidio Domingo-Musibay, MD, Department of Medicine, Medical School